Search

Your search keyword '"Warm, Mathias"' showing total 316 results
Start Over Author "Warm, Mathias"
316 results on '"Warm, Mathias"'

1. PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant

Author

Degenhardt, Tom, Fasching, Peter A., Lüftner, Diana, Müller, Volkmar, Thomssen, Christoph, Schem, Christian, Witzel, Isabell, Decker, Thomas, Tesch, Hans, Kümmel, Sherko, Uleer, Christoph, Wuerstlein, Rachel, Hoffmann, Oliver, Warm, Mathias, Marschner, Norbert, Schinköthe, Timo, Kates, Ronald E., Schumacher, Johannes, Otremba, Burkhard, Zaiss, Matthias, Harbeck, Nadia, and Schmidt, Marcus

Published
2023
Full Text
View/download PDF

2. Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2− metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial

Author

Kieback, Dirk Günter, van Mackelenbergh, Marion Tina, Hielscher, Carsten, Ugur, Mustafa Celalettin, Uleer, Christoph, Zahn, Mark-Oliver, Meyer, Ralf, Kraudelt, Susanne, Stefek, Andrea, Pink, Daniel, Just, Marianne, Kolberg, Hans-Christian, Fehm, Tanja, Malter, Wolfram, Warm, Mathias, Forstbauer, Helmut, Behringer, Dirk, Wortmann, Anke, Rom, Joachim, Lehnert, Antje, Ackermann, Sven, Guth, Dagmar, Simon, Eike, Dünnebacke, Jan, Hönig, Arnd, Ehscheidt, Peter, Gnauert, Karsten, Kühn, Thorsten, von Abel, Ekkehard, Hartkopf, Andreas, Karck, Ulrich, Negwer, Martina, Wacker, Jürgen, Welslau, Manfred, Sagasser, Jaqueline, Heinrichm, Bernhard, Brucker, Cosima, Stauder, Heribert, Gröll, Isolde, Felberbaum, Ricardo, Popovic, Milos, Baerens, Dirk-Toralf, Söling, Ulrike, Zaiss, Matthias, Rauh, Jaqueline, Fietz, Thomas, Schröder, Jan, Voß, Hermann, Mohm, Johannes, Neef, Ute, Rieger, Lorenz, Distelrath, Andrea, Nusch, Arnd, Schmidt, Burkhard, Lüdtke-Heckenkamp, Kerstin, Berghorn, Michael, Busch, Steffi, Schock, Caroline, Metz, Michael, Lorenz, Andreas, Uhlig, Jens, Otremba, Burkhard, Harbeck, N., Fasching, P.A., Wuerstlein, R., Degenhardt, T., Lüftner, D., Kates, R.E., Schumacher, J., Räth, P., Hoffmann, O., Lorenz, R., Decker, T., Reinisch, M., Göhler, T., Staib, P., Gluz, O., Schinköthe, T., and Schmidt, M.

Published
2023
Full Text
View/download PDF

3. Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial

Author

Kolberg-Liedtke, Cornelia, Feuerhake, Friedrich, Garke, Madlen, Christgen, Matthias, Kates, Ronald, Grischke, Eva Maria, Forstbauer, Helmut, Braun, Michael, Warm, Mathias, Hackmann, John, Uleer, Christoph, Aktas, Bahriye, Schumacher, Claudia, Kuemmel, Sherko, Wuerstlein, Rachel, Graeser, Monika, Nitz, Ulrike, Kreipe, Hans, Gluz, Oleg, and Harbeck, Nadia

Published
2022
Full Text
View/download PDF

4. Comparison of the Preoperative MRI Evaluation of Glandular Tissue in Subcutaneous Mastectomy and its Influence on the Implant Volume.

Author

FRITSCH, HANNA, TUMELTSHAMMER, REBECCA, HACHENBERG, JENS, WARM, MATHIAS, KRUG, BARBARA, MALTER, WOLFRAM, and EICHLER, CHRISTIAN

Subjects
BREAST surgery, BREAST implants, MASTECTOMY, BREAST cancer, MAGNETIC resonance imaging, MAMMAPLASTY, MAGNETIC resonance mammography
Abstract

Background/Aim: This study examined the influence of preoperative MRI on the choice of implant volume in patients undergoing subcutaneous mastectomy with immediate breast reconstruction. It was postulated that preoperative MRI scans can adequately estimate glandular tissue, which in turn correlates with implant size. Patients and Methods: Preoperative and postoperative MRI scans were used in oncological and prophylactical subcutaneous mastectomy scenarios in 67 cases at the Department of Gynaecology, Breast Cancer Center, University of Cologne, Germany. The preoperative MRI was used to estimate the resected tissue and the postoperative MRI was used to scan for residual glandular tissue. In addition, a correlation found by Malter et al. in 2021 was evaluated with the available data. Results: Preoperative MRIs result in an adequate estimation of resected tissue. This in turn correlates with implant volume. The correlation by Malter et al. also holds when estimating implant volume. The likelihood of residual gland was low if the preoperatively estimate volume was removed. Conclusion: Our results indicate that the use of preoperative and postoperative MRI scans for subcutaneous mastectomies is advantageous. We suggest a routine estimation of glandular tissue, especially for small breasts. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Best Practice Guideline – Empfehlungen der DEGUM zur Durchführung und Beurteilung der Mammasonografie

Author

Vogel-Minea, Claudia Maria, primary, Bader, Werner, primary, Blohmer, Jens-Uwe, additional, Duda, Volker, additional, Eichler, Christian, additional, Fallenberg, Eva Maria, additional, Farrokh, André, additional, Golatta, Michael, additional, Gruber, Ines, additional, Hackelöer, Bernhard-Joachim, additional, Heil, Jörg, additional, Madjar, Helmut, additional, Marzotko, Ellen, additional, Merz, Eberhard, additional, Müller-Schimpfle, Markus, additional, Mundinger, Alexander, additional, Ohlinger, Ralf, additional, Peisker, Uwe, additional, Schäfer, Fritz KW, additional, Schulz-Wendtland, Ruediger, additional, Solbach, Christine, additional, Warm, Mathias, additional, Watermann, Dirk, additional, Wojcinski, Sebastian, additional, Dudwiesus, Heiko, additional, and Hahn, Markus, additional

Published
2023
Full Text
View/download PDF

7. Supplementary Data: Figures S1-S6 and Tables S1-S6 from Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial

Author

Fasching, Peter A., primary, Szeto, Christopher, primary, Denkert, Carsten, primary, Benz, Stephen, primary, Weber, Karsten, primary, Spilman, Patricia, primary, Budczies, Jan, primary, Schneeweiss, Andreas, primary, Stickeler, Elmar, primary, Schmatloch, Sabine, primary, Jackisch, Christian, primary, Karn, Thomas, primary, Sinn, Hans Peter, primary, Warm, Mathias, primary, van Mackelenbergh, Marion, primary, Rabizadeh, Shahrooz, primary, Schem, Christian, primary, Heinmöller, Ernst, primary, Mueller, Volkmar, primary, Marmé, Frederik, primary, Soon-Shiong, Patrick, primary, Nekljudova, Valentina, primary, Untch, Michael, primary, and Loibl, Sibylle, primary

Published
2023
Full Text
View/download PDF

8. Data from Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial

Author

Fasching, Peter A., primary, Szeto, Christopher, primary, Denkert, Carsten, primary, Benz, Stephen, primary, Weber, Karsten, primary, Spilman, Patricia, primary, Budczies, Jan, primary, Schneeweiss, Andreas, primary, Stickeler, Elmar, primary, Schmatloch, Sabine, primary, Jackisch, Christian, primary, Karn, Thomas, primary, Sinn, Hans Peter, primary, Warm, Mathias, primary, van Mackelenbergh, Marion, primary, Rabizadeh, Shahrooz, primary, Schem, Christian, primary, Heinmöller, Ernst, primary, Mueller, Volkmar, primary, Marmé, Frederik, primary, Soon-Shiong, Patrick, primary, Nekljudova, Valentina, primary, Untch, Michael, primary, and Loibl, Sibylle, primary

Published
2023
Full Text
View/download PDF

9. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

Author

Koroveshi, Dhurata, Bouzid, Kamel, Casalnuovo, Monica, Cascallar, Diana, Korbenfeld, Ernesto Pablo, Bastick, Patricia, Beith, Jane, Colosimo, Maree, Friedlander, Michael, Ganju, Vinod, Green, Michael, Patterson, Kevin, Redfern, Andrew, Richardson, Gary, Ceric, Timur, Gordana, Kecman, Beato, Carlos Augusto, Ferrari, Marcela, Hegg, Roberto, Helena, Vanessa, Ismael, Gustavo Fernando, Lessa, Alvaro Edson, Mano, Max, Morelle, Alessandra, Nogueira, Jose Alberto, Timcheva, Konstanta, Tomova, Antoaneta, Tsakova, Maya, Zlatareva-Petrova, Ani, Asselah, Jamil, Assi, Hazem, Brezden-Masley, Christine, Chia, Stephen, Freedman, Ori, Harb, Mohammed, Joy, Anil Abraham, Kulkarni, Swati, Prady, Catherine, Gaete, Alejandro Andres Acevedo, Matamala, Luis, Torres, Roberto, Yanez, Eduardo, Franco, Sandra, Urrego, Marcela, Gugić, Damir, Vrbanec, Damir, Melichar, Bohuslav, Prausová, Jana, Vyzula, Rostislav, Pilarte, Rafael Gutierrez, León, María Isabel, Muñoz, Rene, Ramos, Glenda, Azeem, Hamdy Abdel, Aziz, Amr Abdel, El Zawahry, Heba, Osegueda, Finlander Rosales, Alexandre, Jerome, Artignan, Xavier, Barletta, Hugues, Beguier, Emmanuel, Berdah, Jean-François, Marty, Chantal Bernard, Bollet, Marc, Bourgeois, Hugues, Bressac, Claude, Burki, Franck, Campone, Mario, Coeffic, David, Cojocarasu, Oana Zveltlana, Dagada, Corinne, Dalenc, Florence, Del Piano, Francesco, Desauw, Christophe, Desmoulins, Isabelle, Dohollou, Nadine, Egreteau, Joelle, Ferrero, Jean-Marc, Foa, Cyril, Garidi, Reda, Gasnault, Laurent, Gligorov, Joseph, Guardiola, Emmanuel, Hamizi, Salima, Jarcau, Rosana, Jacquin, Jean-Philippe, Jaubert, Dominique, Jolimoy, Geneviève, Mineur, Hortense Laharie, Largillier, Remy, Leduc, Bernard, Martin, Philippe, Melis, Adrien, Monge, Jeremy, Moullet, Isabelle, Mousseau, Mireille, Nguyen, Suzanne, Orfeuvre, Hubert, Petit, Thierry, Pivot, Xavier, Priou, Frank, Bach, Isabelle Sillet, Simon, Helene, Stefani, Laetitia, Uwer, Lionel, Youssef, Ali, Aktas, Bahriye, von der Assen, Albert, Augustin, Doris, Balser, Christina, Bauer, Lelia-Eveline, Bechtner, Christina, Beyer, Greta, Brucker, Cosima, Bückner, Ute, Busch, Steffi, Christensen, Bernd, Deryal, Mustafa, Farrokh, Andre, Faust, Elke, Friedrichs, Kay, Graf, Heiko, Griesshammer, Martin, Grischke, Eva-Maria, Hänle, Claudia, Heider, Andrea, Henschen, Stephan, Hesse, Tobias, Jackisch, Christian, Kisro, Jens, Köhler, Andreas, Kuemmel, Sherko, Lampe, Dieter, Lantzsch, Tilmann, Latos, Kunibert, Lex, Benno, Liedtke, Cornelia, Luedders, Doerte, Maintz, Christoph, Müller, Volkmar, Overkamp, Friedrich, Park-Simon, Tjoung-won, Paul, Marion, Prechtl, Anita, Ringsdorf, Uta, Runnebaum, Ingo, Ruth, Sylvia, Salat, Christoph, Scheffen, Iris, Schilling, Jörg, Schmatloch, Sabine, Schmidt, Marcus, Schneeweiss, Andreas, Schrader, Iris, Seipelt, Gernot, Simon, Elke, Stefek, Andrea, Stickeler, Elmar, Thill, Marc, Tio, Joke, Tuczek, Anna, Warm, Mathias, Weigel, Michael, Wischnik, Arthur, Wojcinski, Sebastian, Ziegler-Löhr, Katja, Aravantinos, Gerasimos, Ardavanis, Alexandros, Fountzilas, George, Gogas, Helen, Kakolyris, Stylianos, Mavroudis, Dimitris, Papadimitriou, Christos, Papandreou, Christos, Papazisis, Konstantinos, Castro, Hugo, Hernandez-Monroy, Cesar Estuardo, Ngan, Roger, Yeo, Winnie, Bittner, Nora, Boer, Katalin, Csejtei, Andras, Horvath, Zsolt, Kocsis, Judit, Mangel, László Csaba, Mezei, Klara, Nagy, Zsuzsanna, Szanto, Janos, Atmakusuma, Djumhana, Fadjari, Heri, Kurnianda, Djohan, Prayogo, Nugroho, Tanggo, Eddie Herman, Coate, Linda, Hennessy, Bryan, Kelly, Cathy, Martin, Michael, Nasim, Saira, O'Connor, Miriam, Aieta, Michele, Allegrini, Giacomo, Amadori, Dino, Bidoli, Paolo, Biti, Giampaolo, Bordonaro, Roberto, Bottini, Alberto, Carterni, Giacomo, Cavanna, Luigi, Cazzaniga, Marina, Cognetti, Francesco, Contu, Antonio, Cruciani, Giorgio, Donadio, Michela, Falcone, Alfredo, Farci, Daniele, Forcignanò, R. Chiara, Frassoldati, Antonio, Gaion, Fernando, Gamucci, Teresa, Giotta, Francesco, de Laurentiis, Michele, Livi, Lorenzo, Lorusso, Vito, Maiello, Evaristo, Marchetti, Paolo, Mariani, Gabriella, Mion, Marta, Moscetti, Luca, Musolino, Antonino, Pazzola, Antonio, Pedrazzoli, Paolo, Pigi, Andrea, de Placido, Sabino, Caremoli, Elena Rota, Santoro, Armando, Tienghi, Amelia, Ahn, Jin-Seok, Jung, Kyung Hae, Lee, Keun Seok, Lee, Soo Hyeon, Seo, Jae Hong, Sohn, Joo-Hyuk, Cesas, Alvydas, Juozaityte, Elona, Cheah, Nellie Lay Chin, Chong, Flora Li Tze, Devi, Beena C.R., Phua, Vincent, Teoh, Darren, Ching, Lee Wei, Yusof, Mastura, Corona, Jorge, Dominguez, Adriana, Mendoza, René Lazaro González, Hernandez, Carlos Alberto, Ramiro, Alejandro Juarez, Santos, Juan Matos, Espinosa, Paola Morales, Villarreal Garza, Cynthia Mayte, Errihani, Hassan, Bakker, Sandra, van den Berkmortel, Franchette, Blaisse, R.J.B., Huinink, Daan ten Bokkel, van den Bosch, J., Braun, J.J., Dercksen, M.W., Droogendijk, Helga, Erdkamp, Frans, Haringhuizen, Annebeth, de Jongh, F.E., Kok, T.C., Los, Maartje, Madretsma, Stanley, Terwogt, Jetske M. Meerum, van der Padt, Annemieke, van Rossum-Schornagel, Quirine Clementine, Smilde, T.J., de Valk, Bart, van der Velden, Annette, van Warmerdam, Laurence, van de Wouw, A.J., North, Richard, Kersten, Christian, Mjaaland, Ingvild, Wist, Erik, Aziz, Zeba, Masood, Nehal, Rashid, Kamran, Shah, Mazhar, Alcedo, Juan Carlos, Aleman, Diana, Neciosup, Silvia, Reategui, Rocio, Valdiviezo, Natalia, Vera, Luis, Fernando, Gracieux, Roque, Fernando, Strebel, Heinrik Martin, Krzemieniecki, Krzysztof, Litwiniuk, Maria, Mruk, Andrzej, Pienkowski, Tadeusz, Sawrycki, Piotr, Slomian, Grzegorz, Tomczak, Piotr, Afonso, Noemia, Cardoso, Fátima, Damasceno, Margarida, Nave, Monica, Badulescu, Florinel, Ciule, Larisa, Curescu, Stefan, Eniu, Alexandru, Filip, Dumitru, Grecea, Daniela, Jinga, Dan-Corneliu, Lungulescu, Dan, Oprean, Cristina Marinela, Stanculeanu, Dana Lucia, Turdean, Maria, Dvornichenko, Viktoria, Emelyanov, Sergey, Lichinitser, Mikhail, Manikhas, Alexey, Sakaeva, Dina, Shirinkin, Vadim, Stroyakovskiy, Daniil, Abulkhair, Omalkhair, Zekri, Jamal, Filipovic, Sladjana, Kovcin, Vladimir, Nedovic, Jasmina, Pesic, Jasna, Vasovic, Suzana, Ng, Raymond, Bystricky, Branislav, Leskova, Jaroslava, Mardiak, Jozef, Mišurová, Etela, Wagnerova, Maria, Takač, Iztok, Demetriou, Georgia Savva, Dreosti, Lydia, Govender, Poovandren, Jordaan, Johannes Petrus, Veersamy, Petrosian, Romero, Jose Luis Alonso, Lopez, Norberto Batista, Arias, Carmen Cañabate, Chacon, Jose, Aramburo, Antonio Fernandez, Morales, Luis Antonio Fernandez, Garcia, Mirta, Estevez, Laura Garcia, Garcia-Palomo Perez, Andres, Garcia Saenz, Jose Angel, Garcia Sanchis, Laura, Cubells, Laia Garrigos, Cortijo, Lucia Gonzalez, Santiago, Santiago Gonzalez, De Aranguiz, Blanca Hernando Fernandez, Mañas, José Juan Illarramendi, Gallego, Pedro Jimenez, Cussac, Antonio Llombart, Ferrandiz, Cristina Llorca, Garrido, Maria Lomas, Alvarez, Pilar Lopez, Vega, Jose Manuel Lopez, Del Prado, Purificacion Martinez, Jañez, Noelia Martinez, Murillo, Serafin Morales, Rosales, Adolfo Murias, Jaso, Laura Murillo, Fernandez, Ignacio Pelaez, Martorell, Antonia Perello, Carrion, Ramon Perez, Simon, Sonia Pernas, Alcibar, Arrate Plazaola, Lorenzo, Jose Ponce, Garcia, Vanesa Quiroga, Asensio, Teresa Ramon y Cajal, Maicas, Maria Dolores Torregrosa, Villanueva Silva, Maria Jose, Killander, Fredrika, Svensson, Jan Henry, Fehr, Mathias, Hauser, Nik, Müller, Andreas, Pagani, Olivia, Passmann-Kegel, Heike, Popescu, Razvan, Rabaglio, Manuela, Rauch, Daniel, Schlatter, Christina, Zaman, Khalil, Chang, Tsai-Wang, Huang, Chiun-Sheng, Wang, Hwei-Chung, Yu, Jyh-Cherng, Bandidwattanawong, Chanyoot, Maneechavakajorn, Jedzada, Seetalarom, Kasan, Dejthevaporn, Thitiya (Sirisinha), Somwangprasert, Areewan, Vongsaisuwon, Mawin, Akbulut, Hakan, Altundag, Kadri, Arican, Ali, Bozcuk, Hakan, Eralp, Yesim, Idris, Mohamed, Isikdogan, Abdurrahman, Senol, Coskun Hasan, Sevinc, Alper, Uygun, Kazim, Yucel, Eftal, Yucel, Idris, Yumuk, Fulden, Shparyk, Yaroslav, Voitko, Nataliia, Jaloudi, Mohammed, Adams, Jocelyn, Agrawal, Rajiv, Ahmed, Samreen, Alhasso, Abdulla, Allerton, Rozenn, Anwar, Suhail, Archer, Caroline, Ashford, Richard, Barraclough, Lisa, Bertelli, Gianfilippo, Bishop, Jill, Branson, Tony, Butt, Mohammed, Chakrabarti, Amit, Chakraborti, Prabir, Churn, Mark, Crowley, Clare, Davis, Ruth, Dhadda, Amandeep, Eldeeb, Hany, Fraser, Judith, Hall, Julia, Hickish, Tamas, Hogg, Martin, Howe, Theresa, Joffe, Jonathan, Kelleher, Muireann, Kelly, Stephen, Kendall, Anne, Kristeleit, Hartmut, Lumsden, Graeme, Macmillan, Craig, MacPherson, Iain, Malik, Zafar, Mithal, Natasha, Neal, Anthony, Panwar, Udaiveer, Proctor, Andrew, Proctor, Steven John, Raj, Sanjay, Rehman, Shazza, Sandri, Ines, Scatchard, Kate, Sherwin, Elizabeth, Sims, Eliot, Singer, Julian, Smith, Sarah, Tahir, Saad, Taylor, Wendy, Tsalic, Medy, Verrill, Mark, Wardley, Andrew, Waters, Simon, Wheatley, Duncan, Wright, Kathryn, Yuille, Frances, Alonso, Isabel, Artagaveytia, Nora, Rodriguez, Robinson, Arbona, Esther, Garcia, Yuraima, Lion, Lorena, Marcano, Dalila, Van Thuan, Tran, Gligorov, J., Ataseven, B., Verrill, M., De Laurentiis, M., Jung, K.H., Azim, H.A., Al-Sakaff, N., Lauer, S., Shing, M., and Pivot, X.

Published
2017
Full Text
View/download PDF

10. Safety of Targeted Axillary Dissection After Neoadjuvant Therapy in Patients With Node-Positive Breast Cancer

Author

Kuemmel, Sherko, primary, Heil, Joerg, additional, Bruzas, Simona, additional, Breit, Elisabeth, additional, Schindowski, Dorothea, additional, Harrach, Hakima, additional, Chiari, Ouafaa, additional, Hellerhoff, Karin, additional, Bensmann, Elena, additional, Hanf, Volker, additional, Graßhoff, Sven-Thomas, additional, Deuschle, Petra, additional, Belke, Kerstin, additional, Polata, Silke, additional, Paepke, Stefan, additional, Warm, Mathias, additional, Meiler, Johannes, additional, Schindlbeck, Christian, additional, Ruhwedel, Wencke, additional, Beckmann, Ulrike, additional, Groh, Ulrich, additional, Dall, Peter, additional, Blohmer, Jens-Uwe, additional, Traut, Alexander, additional, and Reinisch, Mattea, additional

Published
2023
Full Text
View/download PDF

11. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto—GBG 69): a randomised, phase 3 trial

Author

Untch, Michael, Jackisch, Christian, Schneeweiss, Andreas, Conrad, Bettina, Aktas, Bahriye, Denkert, Carsten, Eidtmann, Holger, Wiebringhaus, Hermann, Kümmel, Sherko, Hilfrich, Jörn, Warm, Mathias, Paepke, Stefan, Just, Marianne, Hanusch, Claus, Hackmann, John, Blohmer, Jens-Uwe, Clemens, Michael, Darb-Esfahani, Silvia, Schmitt, Wolfgang Daniel, Dan Costa, Serban, Gerber, Bernd, Engels, Knut, Nekljudova, Valentina, Loibl, Sibylle, and von Minckwitz, Gunter

Published
2016
Full Text
View/download PDF

13. Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study

Author

Wallwiener, Markus, Nabieva, Naiba, Feisst, Manuel, Fehm, Tanja, de Waal, Johann, Rezai, Mahdi, Baier, Bernd, Baake, Gerold, Kolberg, Hans-Christian, Guggenberger, Martin, Warm, Mathias, Harbeck, Nadia, Wuerstlein, Rachel, Deuker, Jörg-Uwe, Dall, Peter, Richter, Barbara, Wachsmann, Grischa, Brucker, Cosima, Siebers, Jan Willem, Popovic, Milos, Kuhn, Thomas, Wolf, Christopher, Vollert, Hans-Walter, Breitbach, Georg-Peter, Janni, Wolfgang, Landthaler, Robert, Kohls, Andreas, Rezek, Daniela, Noesselt, Thomas, Fischer, Gunnar, Henschen, Stephan, Praetz, Thomas, Heyl, Volker, Kühn, Thorsten, Krauss, Thomas, Thomssen, Christoph, Hohn, Andre, Tesch, Hans, Mundhenke, Christoph, Hein, Alexander, Rauh, Claudia, Bayer, Christian M., Schmidt, Katja, Belleville, Erik, Brucker, Sara Y., Hadji, Peyman, Beckmann, Matthias W., Wallwiener, Diethelm, Kümmel, Sherko, Hartkopf, Andreas, and Fasching, Peter A.

Published
2019
Full Text
View/download PDF

14. Inferred immune-cell activity is an independent predictor of HER2 negative breast cancer prognosis and response to paclitaxel-based therapy in the GeparSepto trial

Author

Fasching, Peter A., primary, Szeto, Christopher, additional, Denkert, Carsten, additional, Benz, Stephen, additional, Weber, Karsten, additional, Spilman, Patricia, additional, Budczies, Jan, additional, Schneeweiss, Andreas, additional, Stickeler, Elmar, additional, Schmatloch, Sabine, additional, Jackisch, Christian, additional, Karn, Thomas, additional, Sinn, Hans-Peter, additional, Warm, Mathias, additional, van Mackelenbergh, Marion, additional, Rabizadeh, Shahrooz, additional, Schem, Christian, additional, Heinmoeller, Ernst, additional, Mueller, Volkmar, additional, Marme, Frederik, additional, Soon-Shiong, Patrick, additional, Nekljudova, Valentina, additional, Untch, Michael, additional, and Loibl, Sibylle, additional

Published
2023
Full Text
View/download PDF

15. Supplementary Figure from De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial

Author

Gluz, Oleg, primary, Nitz, Ulrike, primary, Kolberg-Liedtke, Cornelia, primary, Prat, Aleix, primary, Christgen, Matthias, primary, Kuemmel, Sherko, primary, Mohammadian, Mohammad Parsa, primary, Gebauer, Daniel, primary, Kates, Ronald, primary, Paré, Laia, primary, Grischke, Eva-Maria, primary, Forstbauer, Helmut, primary, Braun, Michael, primary, Warm, Mathias, primary, Hackmann, John, primary, Uleer, Christoph, primary, Aktas, Bahriye, primary, Schumacher, Claudia, primary, Wuerstlein, Rachel, primary, Graeser, Monika, primary, Pelz, Enrico, primary, Jóźwiak, Katarzyna, primary, zu Eulenburg, Christine, primary, Kreipe, Hans Heinrich, primary, and Harbeck, Nadia, primary

Published
2023
Full Text
View/download PDF

16. Efficacy and safety of nab-paclitaxel 125 mg/m2 and nab-paclitaxel 150 mg/m2 compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69)

Author

Furlanetto, Jenny, Jackisch, Christian, Untch, Michael, Schneeweiss, Andreas, Schmatloch, Sabine, Aktas, Bahriye, Denkert, Carsten, Wiebringhaus, Hermann, Kümmel, Sherko, Warm, Mathias, Paepke, Stefan, Just, Marianne, Hanusch, Claus, Hackmann, John, Blohmer, Jens Uwe, Clemens, Michael, Costa, Serban Dan, Gerber, Bernd, Nekljudova, Valentina, Loibl, Sibylle, and von Minckwitz, Gunter

Published
2017
Full Text
View/download PDF

17. Evaluation of Real-world Data for Breast-MRI BI-RADS IV Lesions

Author

HACHENBERG, JENS, STEINKASSERER, LENA, MALTER, WOLFRAM, THANGARAJAH, FABINSHY, WARM, MATHIAS, GOSSMANN, AXEL, BROD, MARKUS, PAHMEYER, CAROLINE, and EICHLER, CHRISTIAN

Subjects
Pharmacology, Cancer Research, Carcinoma, Intraductal, Noninfiltrating, Humans, Breast Neoplasms, Female, Breast, Magnetic Resonance Imaging, General Biochemistry, Genetics and Molecular Biology, Research Article, Retrospective Studies
Abstract

Background/Aim: Magnetic resonance imaging (MRI) is an important diagnostic tool in the detection of breast cancer. The Breast Center of the municipal Hospital Holweide, Cologne, annually cares for and treats patients with changes in the breast. A special problem is posed by Breast Imaging-Reporting and Data System (BI-RADS) 4 lesions. If a BI-RADS 4 finding is present, is a vacuum biopsy indicated in every case or, if there is already an indication for surgery due to other findings, can the corresponding finding be removed openly without histological clarification? We require real world data regarding the actual in-center likelihood of a BIRADS 4 lesion to be DCIS (Ductal carcinoma in situ) or invasive disease. Patients and Methods: This is a retrospective study of 1,641 patients who received MRI examination in the radiological department of the municipal hospital Holweide in 2012 and 2013. Each BI-RADS 4 finding (or higher) classified by MRI was compared with the final histological result. Results: 347 MRIs showed BI-RADS 4 findings or higher and 280 (80.7%) cases showed benign histology. In 67 (19.3%) cases, histology showed DCIS or invasive carcinoma. Conclusion: BI-RADS 4 lesions have a low probability of malignancy based on real-world data from this center. If there is already an indication for surgery due to other lesions, the patient can also be offered a simultaneous open biopsy in the context of the already initiated surgical treatment. Each center should know the sensitivity and specificity of the MRI imaging performed and counsel patients based on that.

Published
2022
Full Text
View/download PDF

18. A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study

Author

Harbeck, Nadia, Saupe, Steffen, Jäger, Elke, Schmidt, Marcus, Kreienberg, Rolf, Müller, Lothar, Otremba, Burkhard Joerg, Waldenmaier, Dirk, Dorn, Julia, Warm, Mathias, Scholz, Michael, Untch, Michael, de Wit, Maike, Barinoff, Jana, Lück, Hans-Joachim, Harter, Philipp, Augustin, Doris, Harnett, Paul, Beckmann, Matthias W., Al-Batran, Salah-Eddin, and On behalf of the PELICAN Investigators

Published
2017
Full Text
View/download PDF

20. Best Practice Guideline – Empfehlungen der DEGUM zur Durchführung und Beurteilung der Mammasonografie – TEIL I – Untersuchungstechnik, Ultraschall-DEGUM-Kriterien und deren Dokumentation

Author

Bader, Werner, primary, Vogel-Minea, Claudia Maria, primary, Blohmer, Jens-Uwe, additional, Duda, Volker, additional, Eichler, Christian, additional, Fallenberg, Eva, additional, Farrokh, André, additional, Golatta, Michael, additional, Gruber, Ines, additional, Hackelöer, Bernhard-Joachim, additional, Heil, Jörg, additional, Madjar, Helmut, additional, Marzotko, Ellen, additional, Merz, Eberhard, additional, Müller-Schimpfle, Markus, additional, Mundinger, Alexander, additional, Ohlinger, Ralf, additional, Peisker, Uwe, additional, Schäfer, Fritz K. W., additional, Schulz-Wendtland, Ruediger, additional, Solbach, Christine, additional, Warm, Mathias, additional, Watermann, Dirk, additional, Wojcinski, Sebastian, additional, and Hahn, Markus, additional

Published
2022
Full Text
View/download PDF

21. Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2– Early Breast Cancer

Author

Nitz, Ulrike A., primary, Gluz, Oleg, additional, Kümmel, Sherko, additional, Christgen, Matthias, additional, Braun, Michael, additional, Aktas, Bahriye, additional, Lüdtke-Heckenkamp, Kerstin, additional, Forstbauer, Helmut, additional, Grischke, Eva-Maria, additional, Schumacher, Claudia, additional, Darsow, Maren, additional, Krauss, Katja, additional, Nuding, Benno, additional, Thill, Marc, additional, Potenberg, Jochem, additional, Uleer, Christoph, additional, Warm, Mathias, additional, Fischer, Hans Holger, additional, Malter, Wolfram, additional, Hauptmann, Michael, additional, Kates, Ronald E., additional, Gräser, Monika, additional, Würstlein, Rachel, additional, Shak, Steven, additional, Baehner, Frederick, additional, Kreipe, Hans H., additional, and Harbeck, Nadia, additional

Published
2022
Full Text
View/download PDF

22. Concordance and clinical impact of ER, PR, HER2 expression by local and central immunohistochemistry versus RT-PCR in HR+/HER2- early breast cancer (EBC): Results from the ADAPT trial.

Author

Gluz, Oleg, primary, Christgen, Matthias, additional, Kuemmel, Sherko, additional, zu Eulenburg, Christine, additional, Braun, Michael, additional, Aktas, Bahriye, additional, Luedtke-Heckenkamp, Kerstin, additional, Forstbauer, Helmut, additional, Grischke, Eva-Maria, additional, Schumacher, Claudia, additional, Krauss, Katja, additional, Thill, Marc, additional, Warm, Mathias, additional, Graeser, Monika Karla, additional, Wuerstlein, Rachel, additional, Kates, Ronald E., additional, Baehner, Frederick L., additional, Nitz, Ulrike, additional, Kreipe, Hans Heinrich, additional, and Harbeck, Nadia, additional

Published
2022
Full Text
View/download PDF

23. Improving Breast Conserving Surgery Using the Faxitron (R) OR Specimen Radiography System - A Complication Analysis, Cost Evaluation and Literature Review

Author

Eichler, Christian, Westerhoff, Anke, Warm, Mathias, Hanstein, Bettina, Puppe, Julian, Krug, Barbara, Malter, Wolfram, Eichler, Christian, Westerhoff, Anke, Warm, Mathias, Hanstein, Bettina, Puppe, Julian, Krug, Barbara, and Malter, Wolfram

Abstract

Background/Aim: The combination of pre-surgical clip placement and hook-wire guided surgery is considered the gold standard for adequately locating non-palpable lesions during breast conserving surgery. After surgical removal of the segment, radiography is required to confirm clip removal, increasing surgical time, post-surgical complication rates, and cost. Patients and Methods: We performed a retrospective analysis, using the Faxitron (R) in-theater specimen radiography system, of the following primary endpoints: surgical time and complication rates. The secondary endpoints were cost effectiveness and clip-location rates. The Control cohort included breast conserving surgery patients prior to May 2019 (n=150) and the Validation cohort included breast conserving surgery patients after May 2019 (n=53). Results: The analysis showed an improvement in surgical time when using the Faxitron (R) system, which is directly linked to a benefit in cost effectiveness. A numerical benefit in complication rates was also shown. A subgroup analysis showed a significant advantage in surgical time for breast conserving surgery plus sentinel node biopsy and open breast biopsies. Conclusion: Use of the Faxitron (R) system significantly reduces surgical time, which increases cost efficiency while maintaining a low complication rate.

Published
2022

24. Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HP2-Early Breast Cancer

Author

Nitz, Ulrike A., Gluz, Oleg, Kuemmel, Sherko, Christgen, Matthias, Braun, Michael, Aktas, Bahriye, Luedtke-Heckenkamp, Kerstin, Forstbauer, Helmut, Grischke, Eva-Maria, Schumacher, Claudia, Darsow, Maren, Krauss, Katja, Nuding, Benno, Thill, Marc, Potenberg, Jochem, Uleer, Christoph, Warm, Mathias, Fischer, Hans Holger, Malter, Wolfram, Hauptmann, Michael, Kates, Ronald E., Graeser, Monika, Wuerstlein, Rachel, Shak, Steven, Baehner, Frederick, Kreipe, Hans H., Harbeck, Nadia, Nitz, Ulrike A., Gluz, Oleg, Kuemmel, Sherko, Christgen, Matthias, Braun, Michael, Aktas, Bahriye, Luedtke-Heckenkamp, Kerstin, Forstbauer, Helmut, Grischke, Eva-Maria, Schumacher, Claudia, Darsow, Maren, Krauss, Katja, Nuding, Benno, Thill, Marc, Potenberg, Jochem, Uleer, Christoph, Warm, Mathias, Fischer, Hans Holger, Malter, Wolfram, Hauptmann, Michael, Kates, Ronald E., Graeser, Monika, Wuerstlein, Rachel, Shak, Steven, Baehner, Frederick, Kreipe, Hans H., and Harbeck, Nadia

Abstract

PURPOSE To our knowledge, WSG-ADAPT-HR+/HER2- (ClinicalTrials.gov identifier: NCT01779206; n = 5,625 registered) is the first trial combining the 21-gene expression assay (recurrence score [RS]) and response to 3-week preoperative endocrine therapy (ET) to guide systemic therapy in early breast cancer. MATERIALS AND METHODS Baseline and postendocrine Ki67 (Ki67(post)) were evaluated centrally. In the en docrine trial, all patients received exclusively ET: patients with pathologic regional lymph node status (pN) 0-1 (ie, 0-3 involved lymph nodes) entered control arm if RS <= 11 and experimental arm if RS12-25 with ET response (Ki67(post) <= 10%). All other patients (including N0-1 RS12-25 without ET response) received dose-dense chemotherapy (CT) followed by ET in the CT trial. Primary end point of the endocrine trial was non-inferiority of 5-year invasive disease-free survival (5y-iDFS) in experimental (v control) arm; secondary end points included distant DFS, overall survival, and translational research. RESULTS Intention-to-treat population comprised 2,290 patients (n = 1,422 experimental v n = 868 control): 26.3% versus 34.6% premenopausal and 27.4% versus 24.0% pN1. One-sided 95% lower confidence limit of the 5y-iDFS difference was -3.3%, establishing prespecified noninferiority (P = .05). 5y-iDFS was 92.6% (95% CI, 90.8 to 94.0) in experimental versus 93.9% (95% CI, 91.8 to 95.4) in control arm; 5-year distant DFS was 95.6% versus 96.3%, and 5-year overall survival 97.3% versus 98.0%, respectively. Differences were similar in age and nodal subgroups. In N0-1 RS12-25, outcome of ET responders (ET alone) was comparable with that of ET nonresponders (CT) for age > 50 years and superior for age <= 50 years. ET response was more likely with aromatase inhibitors (mostly postmenopausal) than with tamoxifen (mostly premenopausal): 78.1% versus 41.1% (P< .001). ET response was 78.8% in RS0-11, 62.2% in RS12-25, and 32.7% in RS > 25 (n = 4,203, P < .001). CONCLUSION WSG

Published
2022

25. De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial

Author

Gluz, Oleg, Nitz, Ulrike, Kolberg-Liedtke, Cornelia, Prat, Aleix, Christgen, Matthias, Kuemmel, Sherko, Mohammadian, Mohammad Parsa, Gebauer, Daniel, Kates, Ronald, Pare, Laia, Grischke, Eva-Maria, Forstbauer, Helmut, Braun, Michael, Warm, Mathias, Hackmann, John, Uleer, Christoph, Aktas, Bahriye, Schumacher, Claudia, Wuerstlein, Rachel, Graeser, Monika, Pelz, Enrico, Jozwiak, Katarzyna, Zu Eulenburg, Christine, Kreipe, Hans Heinrich, Harbeck, Nadia, Gluz, Oleg, Nitz, Ulrike, Kolberg-Liedtke, Cornelia, Prat, Aleix, Christgen, Matthias, Kuemmel, Sherko, Mohammadian, Mohammad Parsa, Gebauer, Daniel, Kates, Ronald, Pare, Laia, Grischke, Eva-Maria, Forstbauer, Helmut, Braun, Michael, Warm, Mathias, Hackmann, John, Uleer, Christoph, Aktas, Bahriye, Schumacher, Claudia, Wuerstlein, Rachel, Graeser, Monika, Pelz, Enrico, Jozwiak, Katarzyna, Zu Eulenburg, Christine, Kreipe, Hans Heinrich, and Harbeck, Nadia

Abstract

Purpose: Although optimal treatment in early triple-negative breast cancer (TNBC) remains unclear, de-escalated chemother-apy appears to be an option in selected patients within this aggressive subtype. Previous studies have identified several pro -immune factors as prognostic markers in TNBC, but their predictive impact regarding different chemotherapy strategies is still controversial.Experimental Design: ADAPT-TN is a randomized neoadju-vant multicenter phase II trial in early patients with TNBC (n = 336) who were randomized to 12 weeks of nab-paclitaxel 125 mg/m2 thorn gemcitabine or carboplatin d 1,8 q3w. Omission of further (neo-) adjuvant chemotherapy was allowed only in patients with patho-logical complete response [pCR, primary endpoint (ypT0/is, ypN0)]. Secondary invasive/distant disease-free and overall survival (i/dDFS, OS) and translational research objectives included quantification of a predictive impact of markers regard-ing selection for chemotherapy de-escalation, measured by gene expression of 119 genes (including PAM50 subtype) by nCounter platform and stromal tumor-infiltrating lymphocytes (sTIL).Results: After 60 months of median follow-up, 12-week-pCR was favorably associated (HR, 0.24; P = 0.001) with 5y-iDFS of 90.6% versus 62.8%. No survival advantage of carboplatin use was observed, despite a higher pCR rate [HR, 1.04; 95% confidence interval (CI), 0.68-1.59]. Additional anthracycline-containing che-motherapy was not associated with a significant iDFS advantage in pCR patients (HR, 1.29; 95% CI, 0.41-4.02). Beyond pCR rate, nodal status and high sTILs were independently associated with better iDFS, dDFS, and OS by multivariable analysis.Conclusions: Short de-escalated neoadjuvant taxane/platinum-based combination therapy appears to be a promising strategy in early TNBC for using pCR rate as an early decision point for further therapy (de-) escalation together with node-negative status and high sTILs.

Published
2022

27. Additional file 4 of Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial

Author

Kolberg-Liedtke, Cornelia, Feuerhake, Friedrich, Garke, Madlen, Christgen, Matthias, Kates, Ronald, Grischke, Eva Maria, Forstbauer, Helmut, Braun, Michael, Warm, Mathias, Hackmann, John, Uleer, Christoph, Aktas, Bahriye, Schumacher, Claudia, Kuemmel, Sherko, Wuerstlein, Rachel, Graeser, Monika, Nitz, Ulrike, Kreipe, Hans, Gluz, Oleg, and Harbeck, Nadia

Abstract

Additional file 4. Table S1. Mediation analysis for raw sTIL-0 and sTIL-3 measurements as continuous variables. Table S2. Mediation analysis for categorized sTIL-0 and sTIL-3 measurements.

Published
2022
Full Text
View/download PDF

28. Additional file 2 of Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial

Author

Kolberg-Liedtke, Cornelia, Feuerhake, Friedrich, Garke, Madlen, Christgen, Matthias, Kates, Ronald, Grischke, Eva Maria, Forstbauer, Helmut, Braun, Michael, Warm, Mathias, Hackmann, John, Uleer, Christoph, Aktas, Bahriye, Schumacher, Claudia, Kuemmel, Sherko, Wuerstlein, Rachel, Graeser, Monika, Nitz, Ulrike, Kreipe, Hans, Gluz, Oleg, and Harbeck, Nadia

Abstract

Additional file 2. Figure S2. Distribution of semi quantitative measurements of A sTIL-0 and B sTIL-3 (n = 336).

Published
2022
Full Text
View/download PDF

29. Additional file 3 of Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial

Author

Kolberg-Liedtke, Cornelia, Feuerhake, Friedrich, Garke, Madlen, Christgen, Matthias, Kates, Ronald, Grischke, Eva Maria, Forstbauer, Helmut, Braun, Michael, Warm, Mathias, Hackmann, John, Uleer, Christoph, Aktas, Bahriye, Schumacher, Claudia, Kuemmel, Sherko, Wuerstlein, Rachel, Graeser, Monika, Nitz, Ulrike, Kreipe, Hans, Gluz, Oleg, and Harbeck, Nadia

Abstract

Additional file 3. Figure S3. ROC curves and AUC in all patients regarding. A sTIL-0 and B sTIL-3

Published
2022
Full Text
View/download PDF

30. Best Practice Guideline – DEGUM Recommendations on Breast Ultrasound

Author

Bader, Werner, primary, Vogel-Minea, Claudia Maria, primary, Blohmer, Jens-Uwe, additional, Duda, Volker, additional, Eichler, Christian, additional, Fallenberg, Eva, additional, Farrokh, André, additional, Golatta, Michael, additional, Gruber, Ines, additional, Hackelöer, Bernhard-Joachim, additional, Heil, Jörg, additional, Madjar, Helmut, additional, Marzotko, Ellen, additional, Merz, Eberhard, additional, Müller-Schimpfle, Markus, additional, Mundinger, Alexander, additional, Ohlinger, Ralf, additional, Peisker, Uwe, additional, Schäfer, Fritz K. W., additional, Schulz-Wendtland, Ruediger, additional, Solbach, Christine, additional, Warm, Mathias, additional, Watermann, Dirk, additional, Wojcinski, Sebastian, additional, and Hahn, Markus, additional

Published
2021
Full Text
View/download PDF

35. PRECYCLE: Multicenter, Randomized Phase IV Intergroup Trial to Evaluate the Impact of E Health-Based Patient Reported Outcome (PRO) Assessment on Quality of Life in Patients with Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Treated with Palbociclib and an Aromatase Inhibitor- or Palbociclib and Fulvestrant

Author

Degenhardt, Tom, primary, Fasching, Peter A., additional, Lüftner, Diana, additional, Müller, Volkmar, additional, Thomssen, Christoph, additional, Schem, Christian, additional, Witzel, Isabell, additional, Decker, Thomas, additional, Tesch, Hans, additional, Kümmel, Sherko, additional, Uleer, Christoph, additional, Wuerstlein, Rachel, additional, Hoffmann, Oliver, additional, Schumacher, Johannes, additional, Warm, Mathias, additional, Marschner, Norbert, additional, Schinköthe, Timo, additional, Kates, Ronald E., additional, Otremba, Burkhard, additional, Zaiss, Matthias, additional, Harbeck, Nadia, additional, and Schmidt, Marcus, additional

Published
2021
Full Text
View/download PDF

36. Pathological complete response rate and survival in patients with BRCA-associated triple-negative breast cancer after 12 weeks of de-escalated neoadjuvant chemotherapy: Translational results of the WSG-ADAPT TN randomized phase II trial (NCT01815242).

Author

Richters, Lisa Katharina Katharina, primary, Gluz, Oleg, additional, Weber-Lassalle, Nana, additional, Christgen, Matthias, additional, Haverkamp, Heinz, additional, Kuemmel, Sherko, additional, Kayali, Mohamad, additional, Kates, Ronald E., additional, Grischke, Eva-Maria, additional, Braun, Michael, additional, Warm, Mathias, additional, Wuerstlein, Rachel, additional, Ernst, Corinna, additional, Graeser, Monika Karla, additional, Hauke, Jan, additional, Nitz, Ulrike, additional, Kreipe, Hans Heinrich, additional, Schmutzler, Rita K., additional, Hahnen, Eric, additional, and Harbeck, Nadia, additional

Published
2021
Full Text
View/download PDF

37. Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial

Author

Graeser, Monika, primary, Feuerhake, Friedrich, additional, Gluz, Oleg, additional, Volk, Valery, additional, Hauptmann, Michael, additional, Jozwiak, Katarzyna, additional, Christgen, Matthias, additional, Kuemmel, Sherko, additional, Grischke, Eva-Maria, additional, Forstbauer, Helmut, additional, Braun, Michael, additional, Warm, Mathias, additional, Hackmann, John, additional, Uleer, Christoph, additional, Aktas, Bahriye, additional, Schumacher, Claudia, additional, Kolberg-Liedtke, Cornelia, additional, Kates, Ronald, additional, Wuerstlein, Rachel, additional, Nitz, Ulrike, additional, Kreipe, Hans Heinrich, additional, and Harbeck, Nadia, additional

Published
2021
Full Text
View/download PDF

39. Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial

Author

Graeser, Monika, Feuerhake, Friedrich, Gluz, Oleg, Volk, Valery, Hauptmann, Michael, Jozwiak, Katarzyna, Christgen, Matthias, Kuemmel, Sherko, Grischke, Eva-Maria, Forstbauer, Helmut, Braun, Michael, Warm, Mathias, Hackmann, John, Uleer, Christoph, Aktas, Bahriye, Schumacher, Claudia, Kolberg-Liedtke, Cornelia, Kates, Ronald, Wuerstlein, Rachel, Nitz, Ulrike, Kreipe, Hans Heinrich, Harbeck, Nadia, Graeser, Monika, Feuerhake, Friedrich, Gluz, Oleg, Volk, Valery, Hauptmann, Michael, Jozwiak, Katarzyna, Christgen, Matthias, Kuemmel, Sherko, Grischke, Eva-Maria, Forstbauer, Helmut, Braun, Michael, Warm, Mathias, Hackmann, John, Uleer, Christoph, Aktas, Bahriye, Schumacher, Claudia, Kolberg-Liedtke, Cornelia, Kates, Ronald, Wuerstlein, Rachel, Nitz, Ulrike, Kreipe, Hans Heinrich, and Harbeck, Nadia

Abstract

Background The association of early changes in the immune infiltrate during neoadjuvant chemotherapy (NACT) with pathological complete response (pCR) in triple-negative breast cancer (TNBC) remains unexplored. Methods Multiplexed immunohistochemistry was performed in matched tumor biopsies obtained at baseline and after 3 weeks of NACT from 66 patients from the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer (WSG-ADAPT-TN) trial. Association between CD4, CD8, CD73, T cells, PD1-positive CD4 and CD8 cells, and PDL1 levels in stroma and/or tumor at baseline, week 3 and 3-week change with pCR was evaluated with univariable logistic regression. Results Compared with no change in immune cell composition and functional markers, transition from 'cold' to 'hot' (below-median and above-median marker level at baseline, respectively) suggested higher pCR rates for PD1-positive CD4 (tumor: OR=1.55, 95% CI 0.45 to 5.42; stroma: OR=2.65, 95% CI 0.65 to 10.71) and PD1-positive CD8 infiltrates (tumor: OR=1.77, 95% CI 0.60 to 5.20; stroma: OR=1.25, 95% CI 0.41 to 3.84; tumor+stroma: OR=1.62, 95% CI 0.51 to 5.12). No pCR was observed after 'hot-to-cold' transition in PD1-positive CD8 cells. pCR rates appeared lower after hot-to-cold transitions in T cells (tumor: OR=0.26, 95% CI 0.03 to 2.34; stroma: OR=0.35, 95% CI 0.04 to 3.25; tumor+stroma: OR=0.00, 95% CI 0.00 to 1.04) and PD1-positive CD4 cells (tumor: OR=0.60, 95% CI 0.11 to 3.35; stroma: OR=0.22, 95% CI 0.03 to 1.92; tumor+stroma: OR=0.32, 95% CI 0.04 to 2.94). Higher pCR rates collated with 'altered' distribution (levels below-median and above-median in tumor and stroma, respectively) of T cell (OR=3.50, 95% CI 0.84 to 14.56) and PD1-positive CD4 cells (OR=4.50, 95% CI 1.01 to 20.14). Conclusion Our exploratory findings indicate that comprehensive analysis of early immune infilt

Published
2021

40. Pathological complete response rate and survival in patients with BRCA-associated triple-negative breast cancer after 12 weeks of de-escalated neoadjuvant chemotherapy: Translational results of the WSG-ADAPT TN randomized phase II trial (NCT01815242).

Author

Richters, Lisa Katharina Katharina, Gluz, Oleg, Weber-Lassalle, Nana, Christgen, Matthias, Haverkamp, Heinz, Kuemmel, Sherko, Kayali, Mohamad, Kates, Ronald E., Grischke, Eva-Maria, Braun, Michael, Warm, Mathias, Wuerstlein, Rachel, Ernst, Corinna, Graeser, Monika Karla, Hauke, Jan, Nitz, Ulrike, Kreipe, Hans Heinrich, Schmutzler, Rita K., Hahnen, Eric, Harbeck, Nadia, Richters, Lisa Katharina Katharina, Gluz, Oleg, Weber-Lassalle, Nana, Christgen, Matthias, Haverkamp, Heinz, Kuemmel, Sherko, Kayali, Mohamad, Kates, Ronald E., Grischke, Eva-Maria, Braun, Michael, Warm, Mathias, Wuerstlein, Rachel, Ernst, Corinna, Graeser, Monika Karla, Hauke, Jan, Nitz, Ulrike, Kreipe, Hans Heinrich, Schmutzler, Rita K., Hahnen, Eric, and Harbeck, Nadia

Published
2021

41. Preoperative Octenidine Application in Breast Reconstruction Surgery

Author

Hachenberg, Jens, Acis, Ellen, Auer-Schmidt, Maximilian Mattes, Warm, Mathias, Malter, Wolfram, Thangarajah, Fabinshy, Eichler, Christian, Hachenberg, Jens, Acis, Ellen, Auer-Schmidt, Maximilian Mattes, Warm, Mathias, Malter, Wolfram, Thangarajah, Fabinshy, and Eichler, Christian

Abstract

Background/Aim: Postoperative infection in implant-based reconstructive breast surgery is a common problem. The preoperative application of a disinfecting washing agent may reduce postoperative infection rates. This retrospective analysis aimed to evaluate whether preoperative Octenisan (R) application yields a reduction in postoperative complications or infection rates in breast reconstructive surgery. Patients and Methods: Between 2016 and 2019, 127 women received implant-based breast reconstruction at the municipal hospital of Cologne, Holweide, Germany. A total of 197 treatments were performed. After giving consent, patients were asked to use Octenisan (R) wash lotion for five days before breast reconstructive surgery. All patients were asked by a simple questionnaire whether they performed showering and washing according to the proposed protocol. In 96 cases patients did adhere to the protocol. In 101 cases they did not. Patient cohorts were then divided into patients who had applied Octenisan (R) wash lotion and patients who had not. Endpoints were defined as minor complications with no implant loss and major complications with consecutive implant loss. Results: Patient adherence to the application regimen was 48.7%. Overall minor complications occurred in 34.4% with preoperative Octenidine usage and 36.6% without preoperative Octenidine usage. Major complications happened in 7% with preoperative Octenidine and 5% without Octenidine. Overall, there was no significant difference concerning minor or major complication rates. Conclusion: Preoperative washing protocols involving the Octenisan (R) wash lotion is relatively cheap and easy to follow. There is evidence that washing protocols result in a reduction of S. aureus infections leading to a better perioperative outcome. Octenisan (R) is safe to use in implant-based breast reconstructive surgery and is not associated with higher risks for patients. Our study did not yield any significant reduction in periopera

Published
2021

42. Intraoperative central nipple biopsy in nipple-sparing mastectomy- A retrospective analysis of 211 patients

Author

Eichler, Christian, Stephan, Sophia, Thangarajah, Fabinshy, Puppe, Julian, Rahmani, Neda, Kurbacher, Christian, Malter, Wolfram, Warm, Mathias, Eichler, Christian, Stephan, Sophia, Thangarajah, Fabinshy, Puppe, Julian, Rahmani, Neda, Kurbacher, Christian, Malter, Wolfram, and Warm, Mathias

Abstract

Subcutaneous nipple sparing mastectomies (NSM) are an important tool in modern oncoplastic surgery. Especially when an immediate implant-based reconstruction (IBR) is desired, clean margins are of the utmost importance. Central nipple biopsies during surgery serve two main purposes. Most importantly, it is hypothesized that intraoperative pathological evaluation of this biopsy may increase clean margin resection rates. In addition, a general recurrence risk reduction may occur due to the elimination of glandular and ductal components within the nipple. This analysis is a single center, multi-surgeon, retrospective, head to head analysis. Starting in March 2015, intraoperative central nipple biopsy in NSMs with IBR was introduced at the Municipal Breast Cancer Centre Cologne, Holweide, Germany. This trial retrospectively evaluates global complication rates, clean margin status and local recurrence rates for cohort 1 (NSM/no nipple biopsy, n = 103) vs. cohort 2 (NSM with nipple biopsy, n = 108) Median follow-up was 15 months. All implant-based reconstruction procedures used an epipectoral implant pocket. Cohorts were comparable. Global complication rates slightly favored the nipple biopsy cohort with respects to implant loss rate. An involved central nipple biopsy was found in 4.6% (n = 5/108) of the performed NSM procedures leading to the immediate removal of the nipple areola complex. All positive retro-areolar biopsies correlated with a positive nipple biopsy. However, in n = 1 case we found DCIS discontinual proliferation with an involved nipple biopsy, without a correlating positive retro-areolar biopsy (ie, 1 false-negative case was prevented). For the 15 month follow-up, there was no case of local recurrence within nipple areola complex for both cohorts. With this retrospective head to head analysis of 211 patients, it was shown that the central nipple biopsy correlates well with the retro-areolar biopsy. There may be a reduction in false negative rates. The pr

Published
2021

48. ADAPTcycle: Adjuvant dynamic marker-adjusted personalized therapy (ADAPT) comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk HR+/HER2- early breast cancer (EBC).

Author

Harbeck, Nadia, primary, Gluz, Oleg, additional, Christgen, Matthias, additional, Graeser, Monika, additional, Hilpert, Felix, additional, Krauss, Katja, additional, Thill, Marc, additional, Warm, Mathias, additional, Müller, Volkmar, additional, Braun, Michael Wilhelm, additional, Just, Marianne, additional, Kreipe, Hans Heinrich, additional, Nitz, Ulrike, additional, Kates, Ronald E., additional, Schinkoethe, Timo, additional, Wuerstlein, Rachel, additional, and Kuemmel, Sherko, additional

Published
2020
Full Text
View/download PDF

50. Abstract P5-14-22: QT-interval prolongation during the treatment with ribociclib and endocrine agents in patients with hormone receptor-positive, human epidermal growth factor 2-negative metastatic breast cancer: A real-world experience

Author

Kurbacher, Christian M, primary, Schott, Alexander, additional, Kurbacher, Ann T, additional, Herz, Susanne, additional, Fischer, Lotta A, additional, Kurbacher, Jutta A, additional, and Warm, Mathias, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results